Axtria Blogs

Rare Diseases

Challenges Of Accelerating Diagnostic Journies For Rare Diseases

The United States Food and Drug Administration (FDA) defines a rare disease or orphan disease as a disease or state that affects less than 200,000 patients in the US, or that affects no more than five in 10,000 of the general population in the European Union (EU)(1). It is estimated that there over 6,000 different rare diseases identified to date, with around 3/4th of these genetic in origin (1). With genetic as a major etiological factor, rare diseases disproportionately affect children, with 30% of the children with rare diseases unable to survive beyond five years of age (2).

There is no doubt that the development and commercialization of rare diseases is an incredibly difficult area for any company. The challenges are numerous and cover many areas, as broad as economics and disease awareness. And as a result, pharmaceutical companies have traditionally been hesitant to foray into this space. To overcome these challenges, the FDA and other regulatory bodies – legislated the Orphan Drug Act in 1983 to provide the much-needed impetus for the development and commercialization of rare diseases.

Continued advocacy by the FDA and patient groups has created a much-needed drive for rare disease drug development. Since 1983, the FDA has approved drugs and biologics for 800+ rare disease indications (3). The growth of rare disease research is further attested by the fact that in 2019 the Center for Drug Evaluation and Research (CDER) approved 44% of pure orphan products (i.e., 21 out of 48 novel drug approvals were pure orphan products) (3).

Read More
Three Rare Disease Diagnoses Opportunities For AI and Machine Learning

Three Rare Disease Diagnoses Opportunities For AI and Machine Learning

The world of health and medicine has broken countless barriers over the last few scores. Life sciences companies have continued to invest significantly in their research of globally corroding diseases, drug molecules discovery and development, and closely monitored clinical trials, to create industry-approved blockbuster medicines. These drugs, gaining precision with time, are curing more diseases and giving patients a chance at better lives. The pharma journey, however, gets complicated with more in-depth clinical and genetic research, as companies continue to find themselves facing more significant ‘unknowns’ than ever before.

Read More

Quantifying The Economic Burden Of Inadequate Symptom Control Among Patients With IBS-D

As the industry shifts from volume to value based models, it is becoming necessary for Pharmaceutical companies to demonstrate the value their brands deliver through outcomes and evidence based studies. One example of such study is economic burden of inadequate symptom control.

Read More

Quantifying The Economic Burden Of IBS-D

As the industry shifts from volume to value based models, it is becoming necessary for Pharmaceutical companies to demonstrate the value their brands deliver through outcomes and evidence based studies. One example of such study is the economic burden of disease.

Read More

Market Assessment in Oncology Using APLD

At the PMSA annual conference, Axtria’s Sudeep Saha and Celgene’s Jennifer Maurer shared an approach that demonstrated how to use patient-level data in a robust way to estimate market opportunity and product penetration in the field of Oncology.

Read More

Let Us Show You What Axtria’s 

Solutions Can Do For You